Watson I D, Boulton-Jones M, Stewart M J, Henderson I, Payton C D
Ther Drug Monit. 1987 Jun;9(2):139-47. doi: 10.1097/00007691-198706000-00003.
The serum kinetics of an intravenous bolus of a combination of ticarcillin (TIC) (3 g) and clavulanic acid (CLAV) (0.2 g) have been determined in a number of patients with different degrees of renal failure as characterized by creatinine clearance. The volume of distribution for both drugs was unaffected by renal failure. Indices of serum and renal drug clearance were related to the degree of renal failure. TIC was cleared more slowly than CLAV. Anephric patients may have a higher serum clearance of CLAV than patients categorized by creatinine clearance as having severe renal failure; this could be due to an increase in metabolic clearance. Haemodialysis effectively clears both drugs. "Rebound" serum concentrations were consistently observed for TIC, but were observed in only one patient for CLAV. Continuous ambulatory peritoneal dialysis results in significant recovery of both drugs. The dosing requirements for the combination of TIC and CLAV in patients with renal failure are considered.
已在一些以肌酐清除率为特征的不同程度肾衰竭患者中测定了静脉注射一次大剂量替卡西林(TIC)(3克)和克拉维酸(CLAV)(0.2克)组合后的血清动力学。两种药物的分布容积不受肾衰竭影响。血清和肾脏药物清除指数与肾衰竭程度相关。替卡西林的清除比克拉维酸慢。无肾患者的克拉维酸血清清除率可能高于按肌酐清除率分类为严重肾衰竭的患者;这可能是由于代谢清除增加所致。血液透析可有效清除两种药物。替卡西林持续观察到“反弹”血清浓度,但克拉维酸仅在一名患者中观察到。持续非卧床腹膜透析可使两种药物显著恢复。文中考虑了肾衰竭患者中替卡西林和克拉维酸组合的给药要求。